Leerink Partnrs Issues Optimistic Forecast for TMO Earnings

Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) - Analysts at Leerink Partnrs increased their Q3 2025 EPS estimates for shares of Thermo Fisher Scientific in a report issued on Wednesday, July 23rd. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will post earnings of $5.62 per share for the quarter, up from their previous estimate of $5.49. The consensus estimate for Thermo Fisher Scientific's current full-year earnings is $23.28 per share. Leerink Partnrs also issued estimates for Thermo Fisher Scientific's Q4 2025 earnings at $6.41 EPS and Q4 2026 earnings at $6.90 EPS.

Several other analysts also recently commented on the stock. UBS Group lifted their target price on shares of Thermo Fisher Scientific from $460.00 to $500.00 and gave the stock a "neutral" rating in a report on Thursday. The Goldman Sachs Group set a $610.00 price objective on shares of Thermo Fisher Scientific and gave the stock a "buy" rating in a research report on Wednesday, April 23rd. Scotiabank upgraded shares of Thermo Fisher Scientific from a "sector perform" rating to a "sector outperform" rating and set a $590.00 price target for the company in a research report on Friday, July 11th. HSBC reaffirmed a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday. Finally, Raymond James Financial reissued an "outperform" rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat.com, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average price target of $593.00.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock traded up $3.58 during trading on Friday, hitting $478.61. 4,191,526 shares of the stock were exchanged, compared to its average volume of 3,108,119. The stock has a market capitalization of $180.67 billion, a price-to-earnings ratio of 27.68, a price-to-earnings-growth ratio of 2.47 and a beta of 0.77. The company has a current ratio of 1.93, a quick ratio of 1.38 and a debt-to-equity ratio of 0.65. The company has a fifty day moving average price of $413.76 and a 200-day moving average price of $470.22. Thermo Fisher Scientific has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, topping the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. Thermo Fisher Scientific's revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the previous year, the business earned $5.37 EPS.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $1.72 annualized dividend and a yield of 0.36%. Thermo Fisher Scientific's payout ratio is presently 10.09%.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the transaction, the executive vice president directly owned 23,167 shares of the company's stock, valued at approximately $9,960,188.31. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.33% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Community Bank N.A. increased its position in Thermo Fisher Scientific by 20.1% during the 2nd quarter. Community Bank N.A. now owns 5,312 shares of the medical research company's stock valued at $2,154,000 after purchasing an additional 890 shares during the period. Verdence Capital Advisors LLC boosted its stake in Thermo Fisher Scientific by 5.9% in the 2nd quarter. Verdence Capital Advisors LLC now owns 4,481 shares of the medical research company's stock worth $1,817,000 after purchasing an additional 248 shares in the last quarter. Envestnet Portfolio Solutions Inc. raised its position in Thermo Fisher Scientific by 5.6% in the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 34,334 shares of the medical research company's stock worth $13,921,000 after buying an additional 1,816 shares during the last quarter. Concord Wealth Partners raised its position in Thermo Fisher Scientific by 39.5% in the 2nd quarter. Concord Wealth Partners now owns 113 shares of the medical research company's stock worth $46,000 after buying an additional 32 shares during the last quarter. Finally, Vest Financial LLC raised its position in Thermo Fisher Scientific by 39.3% in the 2nd quarter. Vest Financial LLC now owns 4,440 shares of the medical research company's stock worth $1,800,000 after buying an additional 1,252 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.